In a 60-year-old male with longstanding bipolar disorder who is currently taking valproic acid 500 mg twice daily, risperidone 1 mg twice daily, and zolpidem 5 mg at bedtime, and now presents with insomnia, impulsivity, and multiple falls suggestive of an impending manic episode, what is the best psychotropic medication to add?

Increase Risperidone Dose and Discontinue Zolpidem

The best psychotropic option is to increase risperidone to 3-4 mg BID (total 6-8 mg/day) and discontinue zolpidem immediately. This patient is experiencing breakthrough mania despite current treatment, and the evidence strongly supports optimizing his existing antipsychotic rather than adding another agent, while eliminating a medication that may be contributing to falls and paradoxically worsening sleep.

Rationale for Risperidone Dose Optimization

The patient is currently on risperidone 1 mg BID (2 mg/day total), which is subtherapeutic for acute mania. FDA-approved dosing for bipolar mania demonstrates efficacy at 3-6 mg/day in adults, with mean modal doses of 4.1-5.6 mg/day in successful trials 11. His current dose of 2 mg/day falls well below the therapeutic range established in controlled trials.

• Risperidone monotherapy at 1-6 mg/day was superior to placebo for acute manic episodes, with the 3-6 mg/day range showing robust efficacy 1
• When combined with valproate (which this patient is taking), risperidone 1-6 mg/day with mean modal dose of 3.8 mg/day demonstrated superiority over mood stabilizer alone 1
• The combination of risperidone plus valproate has been specifically validated in controlled trials and shows faster remission rates in the first three weeks compared to either agent alone 2

Target dose: Increase to 1.5-2 mg BID initially, then titrate to 2 mg BID (4 mg total daily) within 3-5 days based on response and tolerability. Maximum dose can reach 3 mg BID (6 mg/day) if needed, though doses above 6 mg/day show no additional benefit 1.

Critical Safety Issue: Discontinue Zolpidem

Zolpidem must be stopped immediately for three compelling reasons:

1. Fall Risk in Elderly: At age 60, this patient has already experienced multiple falls due to impulsivity. Zolpidem significantly increases fall risk through next-day residual effects and cognitive impairment 3. Observational studies link hypnotics to increased risk of fractures and major injury 4.

2. Paradoxical Effects: Zolpidem can cause behavioral disinhibition, agitation, and complex behaviors—particularly problematic in someone already experiencing impulsivity from emerging mania 5. The drug may be exacerbating rather than treating his symptoms.

3. Drug Interaction Concerns: The combination of zolpidem with risperidone and valproate increases sedation and cognitive side effects. One case report documented severe catatonia-like sedation from risperidone-valproate interaction 6, and adding zolpidem to this mix compounds risk.

Insomnia in bipolar disorder is a symptom of the underlying mood episode, not a separate condition requiring hypnotic treatment. Treating the mania will resolve the insomnia 7.

Valproate Dose Assessment Required

While not the primary intervention, check valproate level immediately. The patient is on 500 mg BID (1000 mg/day total). Therapeutic range is 50-125 mcg/mL 88. If subtherapeutic, consider increasing valproate to 750 mg BID (1500 mg/day) after checking level, liver function, and CBC 8.

However, prioritize risperidone optimization first since the evidence for combination therapy (risperidone + valproate) is stronger than valproate monotherapy for acute breakthrough mania 12.

Alternative Insomnia Management

Once zolpidem is discontinued, if insomnia persists after 5-7 days of optimized risperidone:

• Increase risperidone's evening dose (e.g., 1 mg AM, 3 mg PM) to leverage its sedating properties
• Consider quetiapine 25-50 mg at bedtime as adjunctive therapy if insomnia remains refractory after mania improves 7
• Cognitive behavioral therapy for insomnia (CBT-I) should be implemented as first-line non-pharmacologic treatment 7

Monitoring Plan

• Week 1: Daily assessment of mania symptoms (irritability, impulsivity, sleep), fall risk, and medication tolerability
• Week 2-3: Twice weekly monitoring as symptoms stabilize
• Labs at Week 2: Valproate level, CBC, LFTs (valproate monitoring) 8
• Extrapyramidal symptoms: Monitor closely with dose increases; risperidone at 2 mg/day may cause EPS 9. If EPS emerge, reduce dose rather than adding anticholinergics 8
• Weight and metabolic parameters: Baseline and monthly for first 3 months given atypical antipsychotic use 8

Common Pitfalls to Avoid

1. Do not add another mood stabilizer or antipsychotic before optimizing existing regimen—this leads to unnecessary polypharmacy 88
2. Do not continue zolpidem "for sleep"—it's contraindicated in this clinical scenario
3. Do not add benzodiazepines for agitation in a 60-year-old with fall history—they increase fall risk and may cause disinhibition 8
4. Do not add antidepressants—they can precipitate or worsen mania 88

This approach is supported by WHO guidelines recommending haloperidol or second-generation antipsychotics for bipolar mania 10, with maintenance treatment continuing at least 2 years after the last episode 10. The strategy optimizes proven efficacy while minimizing polypharmacy and fall risk in an older adult.